Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix鈩?in mice

详细信息	查看全文 | 推荐本文 |

• 作者：Ji Eun Han^a ; Seo Ri Wui^a ; Shin Ae Park^a ; Na Gyong Lee^a ; ^{nglee@sejong.ac.kr} ; Kwang Sung Kim^b ; Yang Je Cho^b ; Hyoung Jin Kim^c ; Hong-Jin Kim^c ; ^{hongjink@cau.ac.kr}
• 关键词：Human papillomavirus vaccine ; Virus-like particle ; CIA06 ; Adjuvant system
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：13 June, 2012
• 卷：30
• 期：28
• 页码：4127-4134
• 文件大小：735 K

摘要

CIA05 is a toll-like receptor (TLR) 4 agonist derived from an Escherichia coli lipopolysaccharide (LPS) mutant and has been shown to have potential as a vaccine adjuvant. In this study, we investigated the immunopotentiating activity of the adjuvant system CIA06, which is comprised of CIA05 and aluminum hydroxide (alum), when used with the human papillomavirus (HPV) L1 virus-like particles (VLPs) vaccine. BALB/c mice were immunized intramuscularly three times at 2-week intervals with HPV16 L1 VLPs alone or in the presence of various combinations of CIA05 and alum, and the immune responses were assessed. We found that the combination of CIA05 and alum at a ratio of 1:50 (designated CIA06B) yielded the highest immune response in terms of serum anti-HPV L1 VLP IgG antibody titers, splenocyte interferon (IFN)-纬 secretion, and antigen-specific memory B cell responses. The immunogenicity of the CIA06B-adjuvanted HPV16/18 L1 VLP vaccine was compared with that of the currently licensed HPV vaccine Cervarix鈩? The CIA06B-adjuvanted vaccine was similar to Cervarix鈩?with regard to eliciting serum antigen-specific IgG antibodies and virus-neutralizing antibodies but more effective at inducing splenic cytokine production and memory B cells. We also observed that the antigen-specific IgG antibody titers, splenic IFN-纬 secretion and memory B cells induced by the CIA06B-adjuvanted HPV vaccine remained high up to 24 weeks post-immunization. Based on these data, we concluded that CIA06B may have potential as an adjuvant in a potent prophylactic vaccine against HPV infection.